Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates - The Massachusetts General Hospital and Radiation Therapy Oncology Group experiences

Seminars in Radiation Oncology

Volumn 15, Issue 1, 2005, Pages 36-41

  Shipley, William U ^a   Zietman, Anthony L ^a   Kaufman, Donald S ^a   Coen, John J ^a   Sandler, Howard M ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURVIVAL; EXPERIENCE; GENERAL HOSPITAL; HUMAN; KIDNEY PRESERVATION; NORTH AMERICA; PATIENT SELECTION; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 12344333215     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2004.07.008     Document Type: Article

References (20)

1. W.U. Shipley, G.R. Prout Jr, A.B. Einstein Jr Treatment of invasive bladder cancer by cisplatin and irradiation in patients unsuited for surgery a high success rate in clinical stage T2 tumors in a National Bladder Cancer Group trial JAMA 258 1987 931 935
2. C.M. Coppin, M.K. Gospodarowicz, K. James Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation J Clin Oncol 14 1996 2901 2907
3. W.U. Shipley, M.A. Rose, T.L. Perrone, C.M. Mannix, N.M. Heney, G.R. Prout Jr Full-dose irradiation for patients with invasive bladder carcinoma clinical and histologic factors prognostic of improved survival J Urol 134 1985 679 683
4. J. Dunst, R. Sauer, K.M. Schrott Organ-sparing treatment of advanced bladder cancer. A 10-year experience Int J Radiat Oncol Biol Phys 30 1994 261 266
5. W.U. Shipley, D.S. Kaufman, E. Zehr Selective bladder preservation by combined modality protocol treatment long-term outcomes of 190 patients with invasive bladder cancer Urology 60 2002 62 68
6. W.U. Shipley, D.S. Kaufman, W.J. Tester An overview of bladder cancer trials in the Radiation Therapy Oncology Group (RTOG) Cancer 97 suppl 2003 2115 2119
7. M.P. Hagan, K.A. Winter, D.S. Kaufman RTOG 97-06; initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy Int J Radiat Oncol Biol Phys 57 2003 665 672
8. A.L. Zietman, D. Sacco, U. Skowronski Organ-conservation in bladder cancer treated by transurethral resection, chemotherapy, and radiation results of urodynamic and quality of life study on long-term survivors J Urol 170 2003 1772 1776
9. W. Tester, A. Porter, S. Asbell Combined modality program with possible organ preservation for invasive bladder carcinoma results of RTOG protocol 85-12 Int J Radiat Oncol Biol Phys 25 1993 783 790
10. W.U. Shipley, K.A. Winter, D.S. Kaufman A Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy initial results of RTOG 89-03 J Clin Oncol 16 1998 3576 3583
11. D.S. Kaufman, D. Raghavan, M. Carducci Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer J Clin Oncol 18 2000 1921 1927
12. H. Von der Maase, S.W. Hansen, J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer results of a large, randomized, multicenter, Phase III study J Clin Oncol 18 17 2000 3068 3077
13. A. Chakravarti, K. Winter, C.L. Wu Expression of the EGFR is associated with improved outcome in muscle invading bladder cancer an RTOG study (Abstract 713) Proc Am Soc Clin Oncol 21 2002 179a
14. J. Bellmunt, V. Guillem, L. Paz-Ares Phase I-II study of paclitaxel, cisplatin and gemcitabine in advanced transitional-cell carcinoma of the urothelium J Clin Oncol 18 8 2000 3247 3255
15. J.J. Coen, N.M. Heney, A.F. Althausen, A.L. Zietman, D.S. Kaufman, W.U. Shipley An update of selective bladder preservation using combined modality treatment in invasive bladder cancer long term outcome reveals a low risk of invasive recurrence and a high probability of bladder preservation J Urol 171 suppl 2004 American Urologic Association, San Francisco, May 2004. Abstract #308
16. A.L. Zietman, J. Grocela, E. Zehr Selective bladder conservation using transurethral resection, chemotherapy and radiation the management and consequences of Ta, T1, Tis recurrence within the retained bladder Urology 58 2001 380 385
17. H. Wijkstrom, U. Norning, M. Lagerkvist Evaluation of clinical staging before cystectomy for transitional cell bladder carcinoma, a long-term follow-up of 276 consecutive patients Br J Urol 81 1998 686 691
18. J.P. Stein, G. Lieskovsky, R. Cote Radical cystectomy in the treatment of invasive bladder cancer long-term results in 1,054 patients J Clin Oncol 9 2001 666 675
19. G. Dalbagni, E. Genega, M. Hashibe Cystectomy for bladder cancer a contemporary series J Urol 165 2001 1111 1116
20. C. Rodel, G.G. Grabenbaer, R. Kuhn Combined modality treatment and selective organ preservation in invasive bladder cancer long-term results J Clin Oncol 20 2002 3061 3071